Scientists have developed a cancer vaccine platform called PROTEXI that leverages pre-existing antiviral immune memory from SARS-CoV-2 infection and vaccination to target tumors, according to a study published in Nature Communications. Researchers from Celloram Inc., University Hospitals, and Case Western Reserve University designed the dendritic cell platform to pair tumor-specific antigens with helper signals derived from Spike protein epitopes, converting dormant immune responses into an antitumor catalyst.
PROTEXI Platform Redirects COVID-19 Immunity Toward Tumors
Traditional cancer vaccines often struggle to generate durable responses, particularly in immune-cold tumors that evade detection. According to Dr. Tej Pareek, Chief Executive Officer of Celloram Inc., the PROTEXI platform bypasses the need to build immune responses from scratch. Instead, it redirects antiviral memories present in billions of people. By pairing tumor-specific antigens with SARS-CoV-2 Spike protein fragments, the vaccine primes the immune system to recognize and attack cancer cells.
Preclinical Results in Melanoma and Breast Cancer Models
In preclinical evaluations involving melanoma and breast cancer models, PROTEXI slowed tumor growth and improved survival rates, as reported by the research team. The platform successfully transformed immune-evasive tumors into targets for the body’s defenses. Furthermore, tests utilizing humanized mouse models with immune cells from COVID-19-vaccinated donors demonstrated that the vaccine leverages CD4+ helper T-cell immunity to reinforce tumor-specific CD8+ cytotoxic T-cell responses.
Preparing for First-in-Human Clinical Trials in Sarcoma
Building on these preclinical findings, Celloram and University Hospitals Cleveland Medical Center are advancing PROTEXI toward clinical evaluation. According to Dr. John Letterio, director of the Angie Fowler Adolescent and Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children’s Hospital, the upcoming trial will focus on patients with sarcoma. Investigators aim to evaluate the safety, feasibility, and immunologic activity of this personalized approach in a setting where therapeutic options remain limited.
Frequently Asked Questions
What is PROTEXI?
PROTEXI is a novel dendritic cell vaccine platform developed by scientists from Celloram Inc., University Hospitals, and Case Western Reserve University to direct pre-existing antiviral immune memory against tumors.
How does the vaccine utilize COVID-19 immunity?
According to the study published in Nature Communications, PROTEXI pairs tumor-specific antigens with SARS-CoV-2 Spike protein epitopes, turning established antiviral CD4+ helper T-cell immunity into a catalyst for antitumor responses.
What are the next steps for the research?
The research team is advancing the platform toward first-in-human clinical trials in partnership with University Hospitals to evaluate safety and efficacy in patients with sarcoma.
What are your thoughts on repurposing antiviral immunity for cancer treatment? Share your perspective in the comments below, or subscribe to our newsletter for ongoing updates in oncology research.
Related reading